Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...
CHICAGO--(BUSINESS WIRE)--Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced positive Phase 2 results for TTHX1114 ...
CLEVELAND - One year post-surgery, patients who underwent Descemet’s stripping automated endothelial keratoplasty (DSAEK) experienced greater cell loss overall compared to those who underwent ...
Québec City, April 14, 2023 - Fuchs' endothelial corneal dystrophy, a degenerative eye disease, causes progressive vision loss that can induce blindness. It is the leading cause of corneal ...
INDIANAPOLIS--(BUSINESS WIRE)--Price Vision Group announced today that it is the first site to initiate patient treatment in a clinical trial evaluating use of an experimental drug treatment in ...
CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...
Add Yahoo as a preferred source to see more of our stories on Google. In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a ...
In a new study, researchers at the University of Oregon's Phil and Penny Knight Campus for Accelerating Scientific Impact used start codon disruption with CRISPR-Cas9 gene editing to prevent Fuchs' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results